{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T20:07:19Z","timestamp":1760386039399,"version":"3.44.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.intimp.2025.115370","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T02:44:00Z","timestamp":1755744240000},"page":"115370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Letter to the editor regarding \u201cefficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study\u201d"],"prefix":"10.1016","volume":"164","author":[{"given":"Joaqu\u00edn","family":"Borr\u00e1s-Blasco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Valcuende-Rosique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Cornejo-Uixeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.115370_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113474","article-title":"Efficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: a two-year real-world study","volume":"143","author":"Zhao","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"S1","key":"10.1016\/j.intimp.2025.115370_bb0010","first-page":"S1130","article-title":"Persistence, current state of the art","volume":"47","author":"Rodriguez","year":"2023","journal-title":"Farm. Hosp."},{"issue":"7","key":"10.1016\/j.intimp.2025.115370_bb0015","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/jdv.15600","article-title":"Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis","volume":"33","author":"De la Cueva Dobao","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"10.1016\/j.intimp.2025.115370_bb0020","first-page":"345","article-title":"El valor de la persistencia en el modelo de la Medicina 5P en enfermedades cr\u00f3nicas","volume":"38","author":"Borr\u00e1s-Blasco","year":"2023","journal-title":"J Healthc Qual Res."},{"issue":"4","key":"10.1016\/j.intimp.2025.115370_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhqr.2025.101123","article-title":"Influencia de la adherencia en el valor de persistencia dentro de la Medicina 6P","volume":"40","author":"Borr\u00e1s-Blasco","year":"2025","journal-title":"J Healthc Qual Res."},{"issue":"2","key":"10.1016\/j.intimp.2025.115370_bb0030","doi-asserted-by":"crossref","DOI":"10.1093\/intqhc\/mzae026","article-title":"Integration of persistence in the 5P-medicine approach for age-related chronic diseases","volume":"36","author":"Borr\u00e1s-Blasco","year":"2024","journal-title":"Int. J. Qual. Health Care"},{"issue":"5","key":"10.1016\/j.intimp.2025.115370_bb0035","first-page":"296","article-title":"Evaluation of persistence, retention rate and prescription pattern of original infliximab and infliximab CT-P13 in biologic-na\u00efve patients with ulcerative colitis","volume":"46","author":"Valcuende-Rosique","year":"2022","journal-title":"Farm. Hosp."},{"issue":"3","key":"10.1016\/j.intimp.2025.115370_bb0040","first-page":"123","article-title":"Persistence after switching from adalimumab biosimilar RAB11022 to adalimumab biosimilar GP2017 in patients with chronic inflammatory rheumatic diseases","volume":"40","author":"Borr\u00e1s-Blasco","year":"2024","journal-title":"J. Pharm. Technol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115370_bb0045","first-page":"45","article-title":"Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis","volume":"49","author":"Borr\u00e1s-Blasco","year":"2025","journal-title":"Farm. Hosp."},{"key":"10.1016\/j.intimp.2025.115370_bb0050","article-title":"Long-term real-world persistence of guselkumab in patients with moderate-to-severe psoriasis","author":"Borr\u00e1s-Blasco","year":"2025","journal-title":"Actas Dermosifiliogr."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692501361X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692501361X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T07:49:41Z","timestamp":1758786581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692501361X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":10,"alternative-id":["S156757692501361X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115370","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter to the editor regarding \u201cefficacy, drug survival, safety and metabolic parameters of ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study\u201d","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115370"}}